Full Text View
Tabular View
No Study Results Posted
Related Studies
Study of Cysteine Hydrochloride for Erythropoietic Protoporphyria
This study has been completed.
Study NCT00004831   Information provided by FDA Office of Orphan Products Development
First Received: February 24, 2000   Last Updated: June 23, 2005   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Erythropoietic Protoporphyria
Additional conditions recognized in this trial
Protoporphyria, Erythropoietic
More general conditions related to this trial
Digestive System Diseases
Genetic Diseases, Inborn
Liver Diseases
Metabolic Diseases
Metabolism, Inborn Errors
Porphyrias
Porphyrias, Hepatic
Skin Diseases
Skin Diseases, Genetic
Skin Diseases, Metabolic
Interventions listed in this trial
cysteine hydrochloride
Sponsors listed in this trial
FDA Office of Orphan Products Development
St. Luke's-Roosevelt Hospital Center


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services